HMOs (Human Milk Oligosaccharides).

B. infantis carries the transporters and glycosidases that let it consume intact human milk oligosaccharides, which most gut organisms cannot. Pairing the two gives the strain a substrate almost no competitor can use.

Members of this species carry fucosidase and sialidase activity that opens HMO structures. Supplying the glycan alongside the organism is the standard synbiotic pairing.

This species uses the simpler HMO fractions and the galactose released when other bifidobacteria break the larger structures. The glycan feeds it directly and through cross-feeding.

Both are milk-derived and both bias the gut toward bifidobacteria, lactoferrin by binding iron away from competing organisms and HMOs by feeding bifidobacteria selectively. They arrive together in milk and are formulated together for that reason.

Colostrum supplies immunoglobulins and growth factors while HMOs supply the decoy glycans and bifidogenic substrate. The two fractions occupy different roles in the same milk matrix.

GOS was developed as a galactose-linked stand-in for milk oligosaccharides and is fermented by an overlapping set of bifidobacteria. Blending the two widens the range of chain lengths on offer.

FOS is fermented rapidly by a broad set of organisms while HMOs are consumed selectively. Together they raise total short chain fatty acid output while keeping a selective component.

Akkermansia lives on host mucin glycans, which share fucose and sialic acid linkages with milk oligosaccharides. The same enzyme families let it use HMO fragments released by other organisms.

Bifidobacteria ferment HMOs to acetate and lactate, which butyrate-producing organisms then convert onward. Supplying butyrate directly covers the end of the chain the glycan starts.

L. reuteri uses the lactate and simple sugars released when bifidobacteria open HMO structures. The pairing sits inside the same cross-feeding chain rather than competing for the intact glycan.

Lactobacilli are largely not primary HMO degraders; they benefit indirectly when bifidobacteria cleave the glycans and release fucose, sialic acid and lactose fragments. So the pairing works through cross-feeding rather than direct substrate use. Stating it the other way round would overclaim the strain's capability.

S. boulardii is not an HMO consumer, so the two do not share a substrate route; any combined effect would run through independent mechanisms in the same lumen. That makes it a co-formulation rather than a synergy in the biochemical sense. Naming the distinction matters because synbiotic labelling often implies substrate matching that does not exist here.

Inulin and HMOs are structurally unrelated and are fermented by overlapping but not identical organisms, so together they broaden which bacteria receive substrate. Inulin ferments quickly and can produce gas at higher doses, while HMO doses are typically much smaller. Combining them adds fermentable load, which is the thing to watch in a sensitive gut.

Pectin feeds a different slice of the community than HMOs do and ferments more slowly and more distally. In combination the fermentation is spread further along the colon rather than concentrated proximally. It also raises viscosity, which is a separate effect on transit.

HMO fermentation by bifidobacteria yields acetate and lactate, which butyrate producers use as feedstock; resistant starch feeds those same butyrate producers directly. The two therefore arrive at overlapping fermentation endpoints from different directions. Cross-feeding is the established mechanism, so this is a substrate argument rather than an outcome one.

PHGG ferments gradually along the colon and is tolerated at doses where faster fructans are not. Alongside a small HMO dose it extends fermentable substrate without concentrating gas production early. The pairing is about tolerance and distribution as much as about which organisms are fed.

Human milk carries both DHA and oligosaccharides, and formulations that aim to reproduce milk composition include both. They act through unrelated mechanisms, one structural in membranes and one microbial in the colon. Describing them as a synergy would overstate it; describing them as a compositional pairing is accurate.

Zinc supports enterocyte turnover and barrier protein expression, while HMOs act on the same barrier indirectly by shaping fermentation and by blocking pathogen adhesion. Both point at mucosal integrity from different sides. Zinc's role here is established nutrition, not an HMO combination finding.

Vitamin D signalling influences epithelial antimicrobial peptide production and regulatory immune balance in the intestine, which is the same interface HMO fermentation products act at. The two arrive by independent routes and are commonly formulated together in early-life nutrition. No candidate study here tested the pairing.

Phospholipids from the milk fat globule membrane and the oligosaccharide fraction are two separate bioactive components of the same fluid, and both are added to formula for that reason. They do not share a mechanism. The pairing is compositional and is worth stating as such rather than dressed up as interaction.